| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Plasmodium falciparum 3D7 (EC50=0.27 μM), HsKRS (IC50=1.8 μM), HepG2 cells (EC50=49 μM), and Cryptosporidium parvum (EC50=2.5 μM) in whole-cell bloodstream are all susceptible to LysRs-IN-2's activity [1].
|
|---|---|
| ln Vivo |
In a mouse model of P. falciparum SCID, LysRs-IN-2 (1.5 mg/kg; PO once daily for 4 days) reduced parasitemia by 90%. In both INF-gamma knockout mice (a mouse model of Cryptosporidium) and NOD SCID gamma mice, parasite shedding is decreased by LysRs-IN-2 (20 mg/kg; orally once daily for 7 days) [1].
|
| Animal Protocol |
Animal/Disease Models: Murine Plasmodium falciparum NODscidIL2Rγnull (SCID) model [1]
Doses: 1.5 mg/kg Route of Administration: Orally one time/day for 4 days Experimental Results: 90% reduction in parasitemia in malaria SCID mouse model. Animal/Disease Models: NOD SCID gamma and INF-γ knockout mouse model (Cryptosporidium mouse model) [1] Doses: 20 mg/kg Route of Administration: Orally one time/day for 7 days Experimental Results: Parasite shedding diminished to This reduction was below detectable levels in INF-γ knockout mice and persisted for 3 weeks after treatment was discontinued. In NOD SCID gamma mice, oral administration at a concentration of 20 mg/kg one time/day for 7 days diminished parasite shedding by 96% compared to paromomycin. |
| References |
| Molecular Formula |
C17H16F3NO4
|
|---|---|
| Molecular Weight |
355.308455467224
|
| Exact Mass |
355.103
|
| CAS # |
2170696-76-9
|
| PubChem CID |
134158252
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
582
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1(CCC(CNC(C2=CC(C3C=C(C=CC=3O2)F)=O)=O)(CC1)O)F
|
| InChi Key |
PJBRCGHQNUWERQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16F3NO4/c18-10-1-2-13-11(7-10)12(22)8-14(25-13)15(23)21-9-16(24)3-5-17(19,20)6-4-16/h1-2,7-8,24H,3-6,9H2,(H,21,23)
|
| Chemical Name |
N-[(4,4-difluoro-1-hydroxycyclohexyl)methyl]-6-fluoro-4-oxochromene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 60 mg/mL (~168.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.5 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 15.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.5 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8144 mL | 14.0722 mL | 28.1444 mL | |
| 5 mM | 0.5629 mL | 2.8144 mL | 5.6289 mL | |
| 10 mM | 0.2814 mL | 1.4072 mL | 2.8144 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
